

Sexually Transmitted Disease Surveillance 2000

**Division of STD Prevention
September 2001**

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for HIV, STD, and TB Prevention
Division of STD Prevention
Atlanta, Georgia 30333

Centers for Disease Control and
PreventionJeffrey P. Koplan, M.D., M.P.H.
Director

National Center for
HIV, STD, and TB PreventionHarold W. Jaffe, M.D.
Acting Director

Division of STD PreventionJack N. Spencer
Acting Director

Statistics and Data Management
BranchOwen J. Devine, Ph.D.
Chief

Melinda L. Flock, M.S.P.H.
Unit Chief

Rose Horsley
Unit Chief

Epidemiology and Surveillance
BranchStuart M. Berman, M.D., Sc.M.
Acting Chief

Surveillance and Special Studies
SectionHillard Weinstock, M.D., M.P.H.
Chief

Copyright Information

All material contained in this report is in the public domain and may be used and reprinted without special permission; citation to source, however, is appreciated.

Suggested Citation

Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance, 2000*. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, September 2001.

Copies can be obtained from the Training and Health Communications Branch, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E-06, Atlanta, Georgia 30333. Printed copies can also be obtained through the Internet on-line ordering system at the web site listed below.

This report is also available by Internet via the CDC home page at: **<http://www.cdc.gov/std/stats/>**

Foreword

“STDs are hidden epidemics of enormous health and economic consequence in the United States. They are hidden because many Americans are reluctant to address sexual health issues in an open way and because of the biologic and social characteristics of these diseases. All Americans have an interest in STD prevention because all communities are impacted by STDs and all individuals directly or indirectly pay for the costs of these diseases. STDs are public health problems that lack easy solutions because they are rooted in human behavior and fundamental societal problems. Indeed, there are many obstacles to effective prevention efforts. The first hurdle will be to confront the reluctance of American society to openly confront issues surrounding sexuality and STDs. Despite the barriers, there are existing individual- and community-based interventions that are effective and can be implemented immediately. That is why a multifaceted approach is necessary to both the individual and community levels.

To successfully prevent STDs, many stakeholders need to redefine their mission, refocus their efforts, modify how they deliver services, and accept new responsibilities. In this process, strong leadership, innovative thinking, partnerships, and adequate resources will be required. The additional investment required to effectively prevent STDs may be considerable, but it is negligible when compared with the likely return on the investment. The process of preventing STDs must be a collaborative one. No one agency, organization, or sector can effectively do it alone; all members of the community must do their part. A successful national initiative to confront and prevent STDs requires widespread public awareness and participation and bold national leadership from the highest levels.”¹

¹Concluding statement from the Institute of Medicine’s Summary Report, *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*, National Academy Press, Washington, DC, 1997, p.43.

Preface

Sexually Transmitted Disease Surveillance, 2000 presents statistics and trends for sexually transmitted diseases (STDs) in the United States through 2000. This annual publication is intended as a reference document for policy makers, program managers, health planners, researchers, and others who are concerned with the public health implications of these diseases. The figures and tables in this edition supersede those in earlier publications of these data.

The surveillance information in this report is based on the following sources of data: (1) case reports from the STD project areas; (2) prevalence data from the Regional Infertility Prevention Programs, STD project areas, the National Job Training Program (formerly the Job Corps), the Jail STD Prevalence Monitoring Projects, the Men Who Have Sex With Men (MSM) Project, the U.S. Army, and the Indian Health Service; (3) sentinel surveillance of gonococcal antimicrobial resistance from the Gonococcal Isolate Surveillance Project (GISP); and (4) national sample surveys implemented by federal and private organizations.

The STD surveillance systems operated by state and local STD control programs, which provide the case report data, are the sources of many of the figures and all of the statistical tables in this publication. These systems are an integral part of program management at all levels of STD prevention and control in the United States. Because of incomplete reporting, the number of STD cases reported to CDC is less than the actual number of cases occurring among the United States population.

Sexually Transmitted Disease Surveillance, 2000 consists of four parts. The **National Profile** contains figures that provide an overview of STD morbidity in the United States. The accompanying text identifies major findings and trends for selected STDs. The **Special Focus Profiles** contain figures and text describing STDs in selected subgroups and populations that are a focus of national and state prevention efforts. The **Detailed Tables** provide statistical information about STDs at the state, county, city, and national levels. The **Appendix** includes the sources and limitations of the data used to produce this report. Included in this section, are Figures A1-A3 that show progress made by states in converting from hardcopy aggregate reporting to electronic line-listed data.

Selected figures and tables in this document identify goals that reflect progress towards some of the Healthy People 2010 (HP2010) national health status objectives for STDs.¹ **Appendix** Table A1 displays progress made towards the HP2010 Priority Area 25, for STDs. These objectives are used as reference points throughout this edition of *Sexually Transmitted Disease Surveillance, 2000*.

Any comments and suggestions that would improve the usefulness of future publications are appreciated and should be sent to Director, Division of STD Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E-02, Atlanta, Georgia, 30333.

¹U.S. Department of Health and Human Services. *Healthy People 2010*. 2nd ed. With Understanding and Improving Health and Objectives for Improving Health. 2 vols. Washington, DC: U.S. Government Printing Office, November 2000.

Acknowledgments

Publication of this report would not have been possible without the contributions of the State and Territorial Health Departments and the Sexually Transmitted Disease Control Programs, the Regional Infertility Prevention Programs, the U.S. Department of Labor, the Indian Health Service, the John Hopkins University Chlamydia Research Laboratory, and the U.S. Army, which provided surveillance data to the Centers for Disease Control and Prevention.

This report was prepared by the following staff and contractors of the Division of STD Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention: Charles Akers, Stu Berman, Susan Bradley, Jim Braxton, Sharon Clanton, Susan Conner, Deblina Datta, Darlene Davis, Owen Devine, Linda Webster Dicker, Melinda Flock, LaZetta Grier, Alesia Jester Harvey, James Heffelfinger, Rose Horsley, Kathleen Hutchins, Christopher Iverson, Richard Kahn, William Levine, Catherine McLean, Debra Mosure, LuEtta Schneider, Maya Sternberg, Katherine Stone, Emmett Swint, Susan Wang, Hillard Weinstock, and Akbar Zaidi.

Production of this and previous reports would not have been possible without the valuable input of Judith R. Wasserheit and William Levine.

Contents

Foreword	v
Preface	vi
Acknowledgments	vii
Figures in the National Profile	ix
Additional Figures in the Special Focus Profiles	x
Tables in the National Profile	xiii
Geographic Divisions of the United States	xvi
National Overview of Sexually Transmitted Diseases, 2000	1

National Profile

Introduction	5
Chlamydia	7
Gonorrhea	15
Syphilis	25
Other Sexually Transmitted Diseases	35

Special Focus Profiles

Introduction	39
STDs in Women and Infants	41
STDs in Adolescents and Young Adults	51
STDs in Racial and Ethnic Minorities	59
STDs Among Men Who Have Sex with Men	65
STDs in Persons Entering Corrections Facilities	69
STDs in the South	75

Tables

National Summary Tables	79
Chlamydia Tables	82
Gonorrhea Tables	92
Syphilis Tables	102
Chancroid Tables	125

Appendix

Sources and Limitations of Data	127
NETSS Figures A1 - A3	134
Healthy People 2010 Table A1	136
Contributors	137

Figures in the National Profile

Chlamydia

Figure 1.	Chlamydia — Number of states that require reporting of <i>Chlamydia trachomatis</i> infections: United States, 1987–2000	10
Figure 2.	Chlamydia — Reported rates: United States, 1984–2000	10
Figure 3.	Chlamydia — Rates by state: United States and outlying areas, 2000	11
Figure 4.	Chlamydia — Rates by region: United States, 1984–2000	11
Figure 5.	Chlamydia — Rates by gender: United States, 1984–2000	12
Figure 6.	Chlamydia — Age- and gender-specific rates: United States, 2000	12
Figure 7.	Chlamydia — Positivity among 15-24 year old women tested in family planning clinics by state, 2000	13
Figure 8.	Chlamydia — Trends in positivity among 15-44 year old women tested in family planning clinics by HHS regions, 1988–2000	13

Gonorrhea

Figure 9.	Gonorrhea — Reported rates: United States, 1970–2000 and the Healthy People year 2010 objective	18
Figure 10.	Gonorrhea — Rates by state: United States and outlying areas, 2000	18
Figure 11.	Gonorrhea — Rates by region: United States, 1981–2000 and the Healthy People year 2010 objective	19
Figure 12.	Gonorrhea — Rates by gender: United States, 1981–2000 and the Healthy People year 2010 objective	19
Figure 13.	Gonorrhea — Rates by race and ethnicity: United States, 1981–2000 and the Healthy People year 2010 objective	20
Figure 14.	Gonorrhea — Age- and gender-specific rates: United States, 2000	20
Figure 15.	Gonorrhea — Positivity among 15-24 year old women tested in family planning clinics by state, 2000	21
Figure 16.	Gonococcal Isolate Surveillance Project (GISP) — Location of participating clinics and regional laboratories: United States, 2000	21
Figure 17.	Gonococcal Isolate Surveillance Project (GISP) — Penicillin and tetracycline resistance among GISP isolates, 2000	22
Figure 18.	Gonococcal Isolate Surveillance Project (GISP) — Percent of <i>Neisseria gonorrhoeae</i> isolates with decreased susceptibility or resistance to ciprofloxacin, 1990–2000	22
Figure 19.	Gonococcal Isolate Surveillance Project (GISP) — Percent of men with gonorrhea who had a previous gonorrhea infection, 1991–2000	23

Syphilis

Figure 20.	Syphilis — Reported cases by stage of illness: United States, 1941–2000	28
Figure 21.	Primary and secondary syphilis — Reported rates: United States, 1970–2000 and the Healthy People year 2010 objective	28
Figure 22.	Primary and secondary syphilis — Rates by state: United States and outlying areas, 2000	29

Figure 23.	Primary and secondary syphilis — Counties with rates above and counties with rates below the Healthy People year 2010 objective: United States, 2000	29
Figure 24.	Primary and secondary syphilis — Rates by region: United States, 1981–2000 and the Healthy People year 2010 objective.	30
Figure 25.	Primary and secondary syphilis — Rates by urban-rural category and geographic region, 2000	30
Figure 26.	Primary and secondary syphilis — Rates by gender: United States, 1981–2000 and the Healthy People year 2010 objective.	31
Figure 27.	Primary and secondary syphilis — Rates by race and ethnicity: United States, 1981–2000 and the Healthy People year 2010 objective	31
Figure 28.	Primary and secondary syphilis — Age- and gender-specific rates: United States, 2000	32
Figure 29.	Congenital syphilis — Reported cases for infants <1 year of age and rates of primary and secondary syphilis among women: United States, 1970–2000	32
Figure 30.	Congenital syphilis — Rates for infants <1 year of age: United States, 1981–2000 and the Healthy People year 2010 objective.	33

Other Sexually Transmitted Diseases

Figure 31.	Chancroid — Reported cases: United States, 1981–2000	36
Figure 32.	Genital herpes — Initial visits to physicians' offices: United States, 1966–2000	36
Figure 33.	Genital herpes simplex virus type 2 infections — Percent seroprevalence according to age in NHANES II (1976–1980) and NHANES III (1988–1994)	37
Figure 34.	Genital warts — Initial visits to physicians' offices: United States, 1966–2000	37
Figure 35.	Nonspecific urethritis — Initial visits to physicians' offices by men: United States, 1966–2000	38
Figure 36.	Trichomonal and other vaginal infections — Initial visits to physicians' offices: United States, 1966–2000	38

Additional Figures in the Special Focus Profiles

STDs in Women and Infants

Figure A.	Chlamydia — Rates for women by state: United States and outlying areas, 2000	45
Figure B.	Gonorrhea — Rates for women by state: United States and outlying areas, 2000	45
Figure C.	Primary and secondary syphilis — Rates for women by state: United States and outlying areas, 2000	46
Figure D.	Congenital syphilis — Rates for infants <1 year of age by state: United States and outlying areas, 2000	46

Figure E.	Congenital syphilis — Cases by prenatal care utilization: United States, 1995-2000	47
Figure F.	Chlamydia — Positivity among 15-24 year old women tested in prenatal clinics by state, 2000	47
Figure G.	Gonorrhea — Positivity among 15-24 year old women tested in prenatal clinics by state, 2000	48
Figure H.	Ectopic pregnancy — Hospitalizations of women 15-44 years of age: United States, 1980-1999	48
Figure I.	Pelvic inflammatory disease — Hospitalizations of women 15-44 years of age: United States, 1980-1999	49
Figure J.	Pelvic inflammatory disease — Initial visits to physicians' offices by women 15-44 years of age: United States, 1980-2000	49

STDs in Adolescents and Young Adults

Figure K.	Chlamydia — Positivity among women tested in family planning clinics by age group: Region X, 1988-2000	54
Figure L.	Chlamydia — Prevalence among 16-24 year-old women entering the National Job Training Program by state of residence, 2000	54
Figure M.	Chlamydia — Positivity among 17-37 year-old women entering the U.S. Army by state of residence, 1999	55
Figure N.	Chlamydia — Positivity among 17-37 year-old men entering the U.S. Army by state of residence, 1999-2000	55
Figure O.	Gonorrhea — Prevalence among 16-24 year-old women entering the National Job Training Program by state of residence, 2000	56
Figure P.	Gonorrhea — Positivity among 17-37 year-old men entering the U.S. Army by state of residence, 1999-2000	56
Figure Q.	Gonorrhea — Age-specific rates among women 10-44 years of age: United States, 1981-2000	57
Figure R.	Gonorrhea — Age-specific rates among men 10-44 years of age: United States, 1981-2000	57
Figure S.	Primary and secondary syphilis — Age-specific rates among women 10-44 years of age: United States, 1981-2000	58
Figure T.	Primary and secondary syphilis — Age-specific rates among men 10-44 years of age: United States, 1981-2000	58

STDs in Racial and Ethnic Minorities

Figure U.	Chlamydia — Positivity among women tested in family planning clinics by race and ethnicity: Region X, 1988-2000	61
Figure V.	Chlamydia — Positivity among 15-30 year old women tested in Indian Health Service Clinics by IHS regions, 2000	61
Figure W.	Gonorrhea — Reported rates for 15-19 year old females by race and ethnicity: United States, 1981-2000	62
Figure X.	Gonorrhea — Reported rates for 15-19 year old males by race and ethnicity: United States, 1981-2000	62
Figure Y.	Primary and secondary syphilis — Reported rates for 15-19 year old females by race and ethnicity: United States, 1981-2000	63

Figure Z.	Primary and secondary syphilis — Reported rates for 15-19 year old males by race and ethnicity: United States, 1981–2000	63
Figure AA.	Congenital syphilis — Rates for infants <1 year of age by mother's race and ethnicity: United States, 1991–2000 and the Healthy People year 2010 objective	64

STDs Among Men Who Have Sex with Men

Figure BB.	MSM Project — Median STD clinic test positivity for chlamydia, gonorrhea, HIV and syphilis prevalence among MSM, by race/ethnicity, 2000.	67
Figure CC.	MSM Project — Median STD clinic test positivity for chlamydia, gonorrhea, and syphilis prevalence among MSM, by self-reported HIV status, 2000	67
Figure DD.	Gonococcal Isolate Surveillance Project (GISP) — Percent of <i>Neisseria gonorrhoeae</i> isolates obtained from MSM for STD clinics in 14 cities, 1998, 1999 and 2000	68

STDs in Persons Entering Corrections Facilities

Figure EE.	Syphilis serologic tests — Percent seroreactivity in women entering juvenile and adult corrections facilities, 2000	71
Figure FF.	Syphilis serologic tests — Percent seroreactivity in men entering juvenile and adult corrections facilities, 2000	71
Figure GG.	Chlamydia — Positivity in women entering juvenile and adult corrections facilities, 2000	72
Figure HH.	Chlamydia — Positivity in men entering juvenile and adult corrections facilities, 2000	72
Figure II.	Gonorrhea — Positivity in women entering juvenile and adult corrections facilities, 2000	73
Figure JJ.	Gonorrhea — Positivity in men entering juvenile and adult corrections facilities, 2000	73

STDs in the South

Figure KK.	South — Primary and secondary syphilis case rates by county, 2000	77
Figure LL.	South — Increases and decreases in cases of primary and secondary syphilis in 2000 compared with 1999 cases, by county	77
Figure MM.	South — Chlamydia case rates by county, 2000	78
Figure NN.	South — Gonorrhea case rates by county, 2000	78

Appendix

Figure A1.	Chlamydia — National Electronic Telecommunications System for Surveillance (NETSS) transmission status by state, 2000	134
Figure A2.	Gonorrhea — National Electronic Telecommunications System for Surveillance (NETSS) transmission status by state, 2000	134
Figure A3.	Primary and secondary syphilis — National Electronic Telecommunications System for Surveillance (NETSS) transmission status by state, 2000	135

Tables in the National Profile

National Summary Tables

Table 1.	Cases of sexually transmitted diseases reported by state health departments and rates per 100,000 civilian population: United States, 1941–2000	79
Table 2.	Reported cases of sexually transmitted disease by gender and reporting source: United States, 2000	81

Chlamydia

Table 3.	Chlamydia — Reported cases and rates by state/area, ranked by rates: United States and outlying areas, 2000	82
Table 4.	Chlamydia — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 1996–2000	83
Table 5.	Chlamydia — Women – Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	84
Table 6.	Chlamydia — Men – Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	85
Table 7.	Chlamydia — Reported cases and rates in selected cities of >200,000 population, ranked by rates: United States and outlying areas, 2000	86
Table 8.	Chlamydia — Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	87
Table 9.	Chlamydia — Women – Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	88
Table 10.	Chlamydia — Men – Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	89
Table 11A.	Chlamydia — Reported cases by age, gender, and race/ethnicity: United States, 1996–2000	90
Table 11B.	Chlamydia — Reported rates per 100,000 population by age, gender, and race/ethnicity: United States, 1996–2000	91

Gonorrhea

Table 12.	Gonorrhea — Reported cases and rates by state/area, ranked by rates: United States and outlying areas, 2000	92
Table 13.	Gonorrhea — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 1996–2000	93
Table 14.	Gonorrhea — Women – Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	94
Table 15.	Gonorrhea — Men – Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	95
Table 16.	Gonorrhea — Reported cases and rates in selected cities of >200,000 population, ranked by rates: United States and outlying areas, 2000	96


Table 17.	Gonorrhea — Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	97
Table 18.	Gonorrhea — Women – Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	98
Table 19.	Gonorrhea — Men – Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	99
Table 20A.	Gonorrhea — Reported cases by age, gender, and race/ethnicity: United States, 1996–2000	100
Table 20B.	Gonorrhea — Reported rates per 100,000 population by age, gender, and race/ethnicity: United States, 1996–2000	101

Syphilis

Table 21.	All stages of syphilis — Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	102
Table 22.	All stages of syphilis — Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	103
Table 23.	Primary and secondary syphilis — Reported cases and rates by state/area, ranked by rates: United States and outlying areas, 2000	104
Table 24.	Primary and secondary syphilis — Counties and independent cities ranked by number of reported cases: United States, 2000	105
Table 25.	Primary and secondary syphilis — Reported cases and rates by state/area and region listed in alphabetical order: United States and outlying areas, 1996–2000	106
Table 26.	Primary and secondary syphilis — Women – Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	107
Table 27.	Primary and secondary syphilis — Men – Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	108
Table 28.	Primary and secondary syphilis — Reported cases and rates in selected cities of >200,000 population, ranked by rates: United States and outlying areas, 2000	109
Table 29.	Primary and secondary syphilis — Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	110
Table 30.	Primary and secondary syphilis — Women – Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	111
Table 31.	Primary and secondary syphilis — Men – Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	112
Table 32A.	Primary and secondary syphilis — Reported cases by age, gender, and race/ethnicity: United States, 1996–2000	114

Table 32B.	Primary and secondary syphilis — Reported rates per 100,000 population by age, gender, and race/ethnicity: United States, 1996–2000	115
Table 33.	Early latent syphilis — Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	116
Table 34.	Early latent syphilis — Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	117
Table 35.	Late and late latent syphilis — Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	118
Table 36.	Late and late latent syphilis — Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	119
Table 37.	Congenital syphilis — Reported cases and rates in infants <1 year of age: United States (excluding outlying areas), 1963–2000	120
Table 38.	Congenital syphilis — Reported cases and rates in infants <1 year of age by state/area, ranked by rates: United States and outlying areas, 2000 . . .	121
Table 39.	Congenital syphilis — Reported cases and rates in infants <1 year of age by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	122
Table 40.	Congenital syphilis — Reported cases and rates in infants <1 year of age in selected cities of >200,000 population, ranked by rates: United States and outlying areas, 2000	123
Table 41.	Congenital syphilis — Reported cases and rates in infants <1 year of age in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	124
Chancroid		
Table 42.	Chancroid — Reported cases and rates by state/area listed in alphabetical order: United States and outlying areas, 1996–2000	125
Table 43.	Chancroid — Reported cases and rates in selected cities of >200,000 population listed in alphabetical order: United States and outlying areas, 1996–2000	126
Appendix		
Table A1.	Healthy People 2010 Sexually Transmitted Diseases Objective Status . . .	136

Geographic Divisions of the United States



West

Alaska
Arizona
California
Colorado
Hawaii
Idaho
Montana
Nevada
New Mexico
Oregon
Utah
Washington
Wyoming

Midwest

Illinois
Indiana
Iowa
Kansas
Michigan
Minnesota
Missouri
Nebraska
North Dakota
Ohio
South Dakota
Wisconsin

South

Alabama
Arkansas
Delaware
District of Columbia
Florida
Georgia
Kentucky
Louisiana
Maryland
Mississippi
North Carolina
Oklahoma
South Carolina
Tennessee
Texas
Virginia
West Virginia

Northeast

Connecticut
Maine
Massachusetts
New Hampshire
New Jersey
New York
Pennsylvania
Rhode Island
Vermont

National Overview of Sexually Transmitted Diseases, 2000

The logo on the cover of *Sexually Transmitted Disease Surveillance, 2000* is a reminder of the multifaceted, national dimensions of the morbidity, mortality, and costs that result from sexually transmitted diseases (STDs) in the United States. It highlights the central role of STD prevention in improving health among women and infants and in promoting HIV prevention. Organized collaboration among interested, committed public and private organizations is the key to reducing STDs and their related health burdens in our population. As noted in the report of the Institute of Medicine, *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*,¹ surveillance is a key component of our efforts to prevent and control these diseases.

This overview summarizes national surveillance data on the three diseases for which we have federally-funded control programs: chlamydia, gonorrhea, and syphilis. Several observations for 2000 are worthy of note.

Chlamydia

In 2000, 702,093 cases of genital *Chlamydia trachomatis* infection were reported to CDC (Table 1). This case count corresponds to a rate of 257.5 cases per 100,000 persons, an increase of 2.3% compared with the rate of 251.6 in 1999. Rates of reported chlamydial infection among women have been increasing annually since the late 1980s when public programs for screening and treatment of women were first established to avert pelvic inflammatory disease and related complications. Chlamydia screening and reporting are likely to expand further in response to the recently implemented Health Plan Employer Data and Information Set (HEDIS) measure for chlamydia screening of sexually active women 15 to 25 years of age who are provided medical care through managed care organizations.² The increase in chlamydia case reports in 2000 most likely represents a continued increase in screening for this infection and also increased use of more sensitive chlamydia screening tests than used in prior years.

In 2000, the overall reported rate of chlamydial infection in the U.S. among women (404.0 cases per 100,000 females) was approximately four times the reported rate among men (102.8 cases per 100,000 males), reflecting the large number of women screened for this disease. However, with the increased availability of urine testing, men are increasingly being tested for chlamydial infection. From 1996 to 2000, the reported chlamydial infection rate in men increased by 71.9% (from 59.8 to 102.8 cases per 100,000 males) compared with a 26.4% increase in women over this period (from 319.5 to 404.0 cases per 100,000 females), reflecting increased screening among men (Tables 5 and 6).

Data from multiple sources on prevalence of chlamydial infection in defined populations have been useful in monitoring disease burden and guiding chlamydia screening programs. In 2000, the median state-specific chlamydia test positivity among women 15 to 24 years who were screened at selected family planning clinics in all states, the District of Columbia, Puerto Rico, and the Virgin Islands was 5.2% (range, 2.3% to 15.8%) (Figure 7), and at selected prenatal clinics in 23 states and

Puerto Rico, 5.9% (range, 2.2% to 14.5%) (Figure F). For economically-disadvantaged women 16 to 24 years who entered the National Job Training Program in 2000, from 30 states and Puerto Rico, the median state-specific prevalence was 11.9% (range, 6.8% to 19.8%) (Figure L). For women 15 to 30 years screened at Indian Health Service (IHS) clinics in four IHS regions, the prevalence ranged from 3.9% to 9.9% (Figure V). For adolescent women entering juvenile detention centers in 24 U.S. counties, the median chlamydia positivity was 15.0% (range, 1.5% to 28.9%) (Figure GG). For male entrants to the U.S. Army who were screened in 1999 and 2000, the overall chlamydia prevalence was 4.7% (range, 1.0% to 11.1% by state of residence) (Figure N). For adolescent men entering juvenile detention centers in 30 counties, the median chlamydia positivity was 6.6% (range, 0.9% to 13.0%) (Figure HH). Although these data on prevalence are not entirely comparable because of differences in the populations screened, in the performance characteristics of the screening tests, and variations in screening criteria, they provide important information on the continuing high burden of disease in the United States.

In parts of the United States where large scale chlamydia screening programs have been instituted, prevalence of disease has declined substantially. During 1988-2000, among 15-to 44-year-old women participating in the screening programs in Health and Human Services (HHS) Region X family planning clinics, chlamydia test positivity declined 59.2% (from 13.0% to 5.3%) (Figure 8). After adjusting trends in chlamydia positivity to account for changes in laboratory test methods and associated increases in test sensitivity, chlamydia test positivity decreased in four of 10 HHS regions from 1999 to 2000, and increased in six regions. Although chlamydia positivity has declined in the past year in some regions, most likely due to the effectiveness of screening and treating women, continued expansion of screening programs to populations with higher prevalence of disease may have contributed to the increases in positivity seen in other regions. See the **Appendix** for the composition of the HHS regions.

Gonorrhea

Following a 73.9% decline in the reported rate of gonorrhea from 1975 (467.7) to 1997 (122.0), overall rates increased in 1998 (131.6) and have since remained essentially unchanged at the 1998 rate (Table 1). The gonorrhea rate for 2000 (131.6 cases per 100,000 persons) remained essentially unchanged from 1999 (132.0 cases per 100,000 persons) and 1998 (131.6 per 100,000 persons) (Table 1). The 2000 rate for gonorrhea exceeds the Healthy People 2010 (HP2010) objective of 19 cases per 100,000 persons.

The gonorrhea rate in the U.S. among females in 2000 was similar to the rate in 1999 (128.3 and 128.7 cases per 100,000 females, respectively) (Table 14). Gender differences in gonorrhea rates in 2000 (female rate 128.3 per 100,000, male rate 134.6 per 100,000) were similar to the gender difference in rates observed in 1999 (Tables 14 and 15). In contrast to the 20 years prior to 1998, which generally exhibited decreasing age-specific rates for gonorrhea, for most 5-year age categories there was little change in the reported rates between 1999 and 2000. As with chlamydia, rates of gonorrhea in women are particularly high in 15- to 19-year-olds, and in men, are highest in the 20- to 24-year age group.

In 2000, new data on gonorrhea prevalence in defined populations were available from several sources. These new data showed continuing high burden of disease in adolescents and young adults in some parts of the United States. Among 15- to 24-year-old women attending selected family planning clinics in 34 states and the Virgin Islands, the median state-specific gonorrhea prevalence was 0.9 (range, 0.0 % to 4.5%) (Figure 15). For women in this age group attending selected

prenatal clinics in 15 states, the median prevalence was 0.9% (range, 0.0% to 3.7%) (Figure G). For 16- to 24-year-old women entering the National Job Training Program in 21 states and Puerto Rico in 2000, the median gonorrhea prevalence was 3.5% (range, 0.9% to 8.5%) (Figure O). For adolescent women entering juvenile detention facilities, the median positivity for gonorrhea was 4.9% (range, 0.5% to 13.0%) (Figure II); the median positivity in adolescent men entering juvenile detention facilities was 2.4% (range, 0.6% to 4.2%) (Figure JJ).

Antimicrobial resistance in *Neisseria gonorrhoeae* remains a continuing concern; the most recent threat has been the increase in fluoroquinolone resistance reported from several Asian countries. Ciprofloxacin is a fluoroquinolone antibiotic that has been recommended for treatment of gonorrhea by CDC; this oral medication is inexpensive and effectively treats gonorrhea with a single dose. Although only 0.4% of *N. gonorrhoeae* isolates tested through the Gonococcal Isolate Surveillance Project (GISP) in 2000 demonstrated resistance to ciprofloxacin, this is a substantial increase from 1998, when only 0.1% of isolates were reported to be resistant. Of note, the proportion of GISP isolates from Honolulu that were resistant to ciprofloxacin remains high and was 14.3% in 2000. This trend reinforces the recommendation made by CDC in 2000 that fluoroquinolones not be used to treat gonorrhea acquired in Hawaii³. In 2000, there was also a high proportion of GISP isolate resistant to ciprofloxacin (5.6%) in Orange County, California. See **Appendix** for a further description of GISP.

Data on characteristics of patients in the GISP sample have been used to obtain information on the sexual orientation of male STD clinic patients with gonorrhea. In 2000, there was a continuing increase in the proportion of GISP isolates from men who have sex with men (MSM). In 2000, the proportion of GISP isolates from MSM increased to 13.9% compared to 13.1% in 1999. In 1988 only 4.0% of isolates were from MSM. The proportional increase in MSM in GISP has corresponded to an absolute increase in gonorrhea cases among MSM at STD clinics in several large cities that participate in GISP.

Syphilis

The National Plan to Eliminate Syphilis from the United States was developed and announced by the Surgeon General in October 1999⁴ in response to several factors, including the important role of syphilis in facilitating the transmission of HIV infection, the differential impact of syphilis on racial and ethnic minorities, and the recent decline in this disease. The 5,979 cases of primary and secondary (P&S) syphilis reported in 2000 were the fewest cases ever reported in the United States. However, the P&S syphilis rate of 2.2 per 100,000 persons (the lowest since national reporting began in 1941) remains substantially above the goal for syphilis elimination of 0.4 case per 100,000 persons (about 1,000 cases per year)⁴ (Table 1), and the HP2010 goal of 0.2 per 100,000 persons.

The number of P&S syphilis cases reported in 2000 was 9.6% lower than the 6,617 cases reported in 1999. However, this decline was substantially less than the reductions of approximately 20% per year since the last major syphilis epidemic peaked in 1990. Although this smaller decline may partially reflect improved case finding and reporting, it also reflects the persistence of this disease in some populations and recent outbreaks in several geographic areas, including outbreaks among MSM.

One factor that greatly facilitates syphilis elimination efforts is that this disease continues to be primarily reported only in specific areas of the country. In 2000, 2,520 (80.2%) of the 3,139 counties in the United States reported no cases of P&S syphilis (see **Appendix** for details on county coding).

Half of all the P&S syphilis cases were reported from only 21 counties and one city (0.7% of total number of U.S. counties) (Table 24). However, the 2000 P&S syphilis rates were greater than the HP2010 objective in 595 counties (18.9% of the total number of U.S. counties). These 595 counties accounted for more than 99.5% of all reported P&S syphilis cases (5,952 out of 5,979 cases). Sixty-nine percent (412 out of 595) of these counties are located in the southern part of the United States. These data suggest that comprehensive syphilis prevention efforts focused in the South could markedly reduce the number of syphilis cases occurring in the United States.

Between 1999 and 2000, the national rate of congenital syphilis decreased by 7.6%, from 14.5 to 13.4 cases per 100,000 live births (Table 39). The continuing reduction in congenital syphilis rates, occurring since the early 1990s, reflects the substantial reduction in the rate of P&S syphilis among women over the same period. In 2000, approximately one half of the states and outlying areas had a reported rate of congenital syphilis that was greater than the HP2010 objective of 1.0 case per 100,000 live births (Table 38).

Although wide disparities exist in the reported rates of STDs among racial and ethnic groups, there has been a reduction in these differences for some diseases over the past five years. For example, the P&S syphilis rate reported for 2000 among African-Americans was 21 times the rate reported among whites, reflecting a substantial decline from 1996, when the rate among African-Americans was 50 times greater than that among whites (Table 32B). Although reporting biases likely magnify differences in reported rates by race and ethnicity, these factors continue to be risk markers among the U.S. population that correlate with other, more fundamental determinants of health status such as socioeconomic status and access to quality medical care.

¹Institute of Medicine. *The Hidden Epidemic: Confronting Sexually Transmitted Diseases*, Committee on Prevention and Control of Sexually Transmitted Diseases, National Academy Press, Washington, DC, 1997.

²National Committee for Quality Assurance (NCQA). *HEDIS 2000: Technical Specifications*, Washington, DC, 1999, pp. 68-70, 285-286.

³Centers for Disease Control and Prevention. Fluoroquinolone-resistance in *Neisseria gonorrhoeae*, Hawaii, 1999, and decreased susceptibility to azithromycin in *N. Gonorrhoeae*, Missouri, 1999. *MMWR* 2000;49:833-837.

⁴Division of STD Prevention. *The National Plan to Eliminate Syphilis from the United States*. National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1999.